Japan Again Postpones Approval Of Shionogi COVID Antiviral

Decision To Await Phase III Data

 
• By Lisa Takagi and Ian Haydock

Xocova’s emergency approval stymied by uncertainties over efficacy and other characteristics that could effectively limit its use, prompting decision to await Phase III data later this year.

MHLW's Discussion gathered nation-wide attention in Japan
Two-hour long discussion by MHLW gathered nation-wide attention • Source: Lisa Takagi

More from Japan

More from Focus On Asia